502 results on '"Brouwers, Adrienne H."'
Search Results
52. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT
53. Optimization of parathyroid 11C-choline PET protocol for localization of parathyroid adenomas in patients with primary hyperparathyroidism
54. Optimisation of scan duration and image quality in oncological 89Zr immunoPET imaging using the Biograph Vision PET/CT.
55. Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis
56. [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
57. Patient-derived parathyroid organoids as a tracer and drug-screening application model
58. Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations
59. Progressive diastolic dysfunction in survivors of pediatric differentiated thyroid carcinoma
60. Localization of parathyroid adenomas using 11C-methionine pet after prior inconclusive imaging
61. Molecular imaging to support cancer immunotherapy
62. HTP PET-CT
63. Dopa PET-CT
64. Volume of interest delineation techniques for 18F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study
65. 89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer
66. Patient-derived parathyroid organoids as tracer and drug-screening application model
67. Quality Indicators for the Diagnosis and Management of Primary Hyperparathyroidism
68. Additional file 1 of Shortened duration whole body 18F-FDG PET Patlak imaging on the Biograph Vision Quadra PET/CT using a population-averaged input function
69. Additional file 1 of Convolutional neural networks for automatic image quality control and EARL compliance of PET images
70. Lymphatic drainage patterns of oral maxillary tumors: Approachable locations of sentinel lymph nodes mainly at the cervical neck level
71. Additional value of a high sensitive thyroglobulin assay in the follow‐up of patients with differentiated thyroid carcinoma
72. Tailored imaging of islet cell tumors of the pancreas amidst increasing options
73. Convolutional Neural Networks for Automatic Image Quality Control and EARL Compliance of PET Images
74. Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: A Longitudinal Follow-Up Study
75. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients
76. Pediatric Differentiated Thyroid Carcinoma in The Netherlands: A Nationwide Follow-Up Study
77. Shortened duration whole body 18F-FDG PET Patlak imaging on the Biograph Vision Quadra PET/CT using a population-averaged input function.
78. 89Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
79. Other Radiopharmaceuticals for Imaging GEP-NET
80. Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer
81. Nuclear Medicine Imaging of Neuroendocrine Tumors
82. Bone Marrow Function After 131I Therapy in Patients With Differentiated Thyroid Carcinoma
83. First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
84. Abstract LB037: 89ZED88082A PET imaging to visualize CD8+ T cells in patients with cancer treated with immune checkpoint inhibitor
85. The Effects of Molar Activity on [18f]FDOPA Uptake in Patients With Neuroendocrine Tumors.
86. Whole-body CD8+T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
87. DekkerSupplementaldata.docx
88. Progressive Diastolic Dysfunction in Survivors of Pediatric DTC - Supplemental Data
89. Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy.
90. The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
91. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour
92. Considerations on absence of 68Ga-DOTA-F(ab′)2-trastuzumab tracer uptake in HER2-overexpressing tumor lesions
93. [18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial.
94. 18F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions
95. Molecular imaging for monitoring treatment response in breast cancer patients
96. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms
97. Zr-89-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck
98. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma
99. Non‐adherence to consensus guidelines on preoperative imaging in surgery for primary hyperparathyroidism
100. SPECT and PET Imaging of Multidrug Resistance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.